-$0.15 EPS Expected for Agile Therapeutics Inc (AGRX) This Quarter
Equities research analysts expect Agile Therapeutics Inc (NASDAQ:AGRX) to post earnings of ($0.15) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Agile Therapeutics’ earnings, with estimates ranging from ($0.17) to ($0.13). Agile Therapeutics reported earnings per share of ($0.22) in the same quarter last year, which would suggest a positive year-over-year growth rate of 31.8%. The firm is scheduled to issue its next earnings results on Monday, November 5th.
According to Zacks, analysts expect that Agile Therapeutics will report full year earnings of ($0.60) per share for the current financial year, with EPS estimates ranging from ($0.63) to ($0.56). For the next year, analysts expect that the business will report earnings of ($0.64) per share, with EPS estimates ranging from ($0.94) to ($0.41). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Agile Therapeutics.
Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Friday, August 3rd. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01.
AGRX stock traded up $0.13 on Friday, hitting $0.74. 7,710,743 shares of the company’s stock traded hands, compared to its average volume of 1,364,471. Agile Therapeutics has a 1-year low of $0.23 and a 1-year high of $5.37. The firm has a market cap of $12.60 million, a PE ratio of -0.81 and a beta of 1.43.
In related news, insider Life Sciences Maste Perceptive sold 298,628 shares of the company’s stock in a transaction that occurred on Thursday, July 26th. The shares were sold at an average price of $0.30, for a total value of $89,588.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.30% of the stock is currently owned by corporate insiders.
Several large investors have recently modified their holdings of AGRX. A.R.T. Advisors LLC lifted its position in shares of Agile Therapeutics by 82.3% in the 1st quarter. A.R.T. Advisors LLC now owns 66,426 shares of the specialty pharmaceutical company’s stock valued at $170,000 after acquiring an additional 29,995 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Agile Therapeutics by 62.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after acquiring an additional 55,937 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Agile Therapeutics by 76.3% in the 2nd quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after acquiring an additional 343,290 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of Agile Therapeutics by 17.0% in the 1st quarter. Franklin Resources Inc. now owns 3,355,200 shares of the specialty pharmaceutical company’s stock valued at $8,623,000 after acquiring an additional 487,400 shares in the last quarter. Institutional investors and hedge funds own 52.00% of the company’s stock.
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Featured Article: Closed-End Mutual Funds (CEFs)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.